Jeffrey Humphrey - 03 Feb 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Feb 2023, 15:43:21 UTC
Prior SEC filing: 01 Aug 2022
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam M. Veness, as attorney-in-fact for Jeffrey Humphrey

Key filing fact

Jeffrey Humphrey filed Form 4 for Cyteir Therapeutics, Inc. on 07 Feb 2023.

Key facts

This page summarizes Jeffrey Humphrey's Form 4 filing for Cyteir Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Feb 2023, 15:43.

Change

Previous filing in this sequence was filed on 01 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,150
Change %
Price: $0.000000
Shares after: 14,150
Date: 03 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,150
Exercise price: $1.69
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney